Avonex

Biogen Idec posts solid Q4 results and says more to come

MS drugs Tysabri and Avonex lift sales. Solid growth of Biogen Idec's multiple sclerosis (MS) drugs Tysabri and Avonex helped lift the company's fourth quarter revenues by 7 per ... Tysabri (natalizumab) continued its run of growth with a 10 per cent

A new dogma in HTA assessment

Novartis faced similar difficulties in the UK when its multiple sclerosis drug Gilenya was declined by the National Institute for Health and Clinical Excellence (NICE) due to its comparator, Avonex, not

Avonex

Avonex campaign. Created by Seven Stones for Biogen Idec. Therapy area: Central Nervous System

Trial finds Sanofi's teriflunomide no better than Rebif

which has the world's largest MS franchise at the moment headed by its Avonex (interferon beta-1a) product.

Genzyme appoints MS and rare diseases business leaders

Sibold has more than 20 years of experience in the biopharmaceutical industry, including eight years at Biogen Idec where he worked on multiple sclerosis products Avonex and Tysabri.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]